EP0857784B1 - Method for producing L-lysine - Google Patents

Method for producing L-lysine Download PDF

Info

Publication number
EP0857784B1
EP0857784B1 EP97121444A EP97121444A EP0857784B1 EP 0857784 B1 EP0857784 B1 EP 0857784B1 EP 97121444 A EP97121444 A EP 97121444A EP 97121444 A EP97121444 A EP 97121444A EP 0857784 B1 EP0857784 B1 EP 0857784B1
Authority
EP
European Patent Office
Prior art keywords
dna
lysine
amino acid
seq
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97121444A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0857784A2 (en
EP0857784A3 (en
Inventor
Atsushi c/o Ajinomoto Co. Inc. Hayakawa
Masakazu c/o Ajinomoto Co. Inc. Sugimoto
Yasuhiko c/o Ajinomoto Co. Inc. Yoshihara
Tsuyoshi c/o Ajinomoto Co. Inc. Nakamatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18179283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0857784(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of EP0857784A2 publication Critical patent/EP0857784A2/en
Publication of EP0857784A3 publication Critical patent/EP0857784A3/en
Application granted granted Critical
Publication of EP0857784B1 publication Critical patent/EP0857784B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1217—Phosphotransferases with a carboxyl group as acceptor (2.7.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine

Definitions

  • the present invention relates to a method for producing L-lysine by cultivating a microorganism obtained by modifying a coryneform bacterium used for fermentative production of amino acid or the like by means of a technique based on genetic engineering.
  • L-Lysine which is used as a fodder additive, is usually produced by a fermentative method by using an L-lysine-producing mutant strain belonging to the coryneform bacteria.
  • L-lysine-producing bacteria known at present are those created by artificial mutation starting from wild type strains belonging to the coryneform bacteria.
  • coryneform bacteria there are disclosed a vector plasmid which is autonomously replicable in bacterial cells and has a drug resistance marker gene (see United States Patent No. 4,514,502), and a method for introducing a gene into bacterial cells (for example, Japanese Patent Application Laid-open No. 2-207791). There is also disclosed a possibility for breeding an L-threonine- or L-isoleucine-producing bacterium by using the techniques as described above (see United States Patent Nos. 4,452,890 and 4,442,208).
  • Known genes for L-lysine biosynthesis include, for example, a dihydrodipicolinate reductase gene (Japanese Patent Application Laid-open No. 7-75578) and a diaminopimelate dehydrogenase gene (Ishino, S. et al., Nucleic Acids Res. , 15 , 3917 (1987)) in which a gene participating in L-lysine biosynthesis is cloned, as well as a phosphoenolpyruvate carboxylase gene (Japanese Patent Application Laid-open No. 60-87788), a dihydrodipicolinate synthase gene (Japanese Patent Publication No. 6-55149), and a diaminopimelate decarboxylase gene (Japanese Patent Application Laid-open No. 60-62994) in which amplification of a gene affects L-lysine productivity.
  • a dihydrodipicolinate reductase gene Japanese
  • An object of the present invention is to improve the L-lysine yield without restraining the growth of a coryneform bacterium, by enhancing a plurality of genes for L-lysine biosynthesis in combination in the coryneform bacteria.
  • the present invention proposes a solution for the problem as described above in order to fermentatively produce L-lysine by using a coryneform bacterium.
  • the principle of the present invention is based on the fact that the growth of a coryneform bacterium can be improved, and the L-lysine-producing speed thereof can be improved by enhancing both of a DNA sequence coding for an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and a DNA sequence coding for a diaminopimelate decarboxylase compared with the case in which these DNA sequences are each enhanced singly.
  • a recombinant DNA autonomously replicable in cells of coryneform bacteria comprising a DNA sequence coding for an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and a DNA sequence coding for a diaminopimelate decarboxylase.
  • the recombinant DNA further comprising a DNA sequence coding for a phosphoenolpyruvate carboxylase is also provided.
  • a coryneform bacterium harboring an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and comprising an enhanced DNA sequence coding for a diaminopimelate decarboxylase.
  • the coryneform bacterium further comprising an enhanced DNA sequence coding for a phosphoenolpyruvate carboxylase is also provided.
  • a method for producing L-lysine comprising the steps of cultivating any of coryneform bacteria as described in the above in an appropriate medium to allow L-lysine to be produced and accumulated in a culture of the bacterium, and collecting L-lysine from the culture.
  • AK aspartokinase
  • lysC a gene coding for AK
  • mutant AK a gene coding for mutant AK
  • DDC diaminopimelate decarboxylase
  • PEPC phosphoenolpyruvate carboxylase
  • ppc a gene coding for PEPC
  • the coryneform bacteria referred to in the present invention are a group of microorganisms as defined in Bergey's Manual of Determinative Bacteriology , 8th ed. , p. 599 (1974), which are aerobic Gram-positive non-acid-fast rods having no spore-forming ability.
  • the coryneform bacteria include bacteria belonging to the genus Corynebacterium , bacteria belonging to the genus Brevibacterium having been hitherto classified into the genus Brevibacterium but united as bacteria belonging to the genus Corynebacterium at present, and bacteria belonging to the genus Brevibacterium closely relative to bacteria belonging to the genus Corynebacterium .
  • a production amount and a production speed of L-lysine of coryneform bacteria can be improved.
  • the genes for L-lysine biosynthesis used in the present invention are obtained respectively by preparing chromosomal DNA from a bacterium as a DNA donor, constructing a chromosomal DNA library by using a plasmid vector or the like, selecting a strain harboring a desired gene, and recovering, from the selected strain, recombinant DNA into which the gene has been inserted.
  • the DNA donor for the gene for L-lysine used in the present invention is not specifically limited provided that the desired gene for L-lysine biosynthesis expresses an enzyme protein which functions in cells of coryneform bacteria.
  • the DNA donor is preferably a coryneform bacterium.
  • genes of lysC , dapA , and ppc originating from coryneform bacteria have known sequences. Accordingly, they can be obtained by performing amplification in accordance with the polymerase chain reaction method (PCR; see White, T. J. et al., Trends Genet. , 5 , 185 (1989)).
  • a DNA fragment containing mutant lysC can be prepared from a mutant strain in which synergistic feedback inhibition on the AK activity by L-lysine and L-threonine is substantially desensitized (International Publication Pamphlet of WO 94/25605).
  • Such a mutant strain can be obtained, for example, from a group of cells originating from a wild type strain of a coryneform bacterium subjected to a mutation treatment by applying an ordinary mutation treatment such as ultraviolet irradiation and treatment with a mutating agent such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG).
  • the AK activity can be measured by using a method described by Miyajima, R. et al.
  • mutant strain represented by an L-lysine-producing bacterium AJ3445 (FERM P-1944) derived by a mutation treatment from a wild type strain of Brevibacterium lactofermentum ATCC 13869 (having its changed present name of Corynebacterium glutamicum ).
  • mutant lysC is also obtainable by an in vitro mutation treatment of plasmid DNA containing wild type lysC .
  • information is specifically known on mutation to desensitize synergistic feedback inhibition on AK by L-lysine and L-threonine (International Publication Pamphlet of WO 94/25605).
  • mutant lysC can be also prepared from wild type lysC on the basis of the information in accordance with, for example, the site-directed mutagenesis method.
  • a fragment comprising lysC can be isolated from a coryneform bacterium by preparing chromosomal DNA in accordance with, for example, a method of Saito and Miura (H. Saito and K. Miura, Biochem. Biophys. Acta , 72 , 619 (1963)), and amplifying lysC in accordance with the polymerase chain reaction method (PCR; see White, T. J. et al., Trends Genet. , 5 , 185 (1989)).
  • PCR polymerase chain reaction method
  • DNA primers are exemplified by single strand DNA's of 23-mer and 21-mer having nucleotide sequences shown in SEQ ID NOs: 1 and 2 in Sequence Listing in order to amplify, for example, a region of about 1,643 bp coding for lysC based on a sequence known for Corynebacterium glutamicum (see Molecular Microbiology (1991), 5 (5) , 1197-1204; Mol. Gen. Genet. (1990), 224 , 317-324).
  • DNA can be synthesized in accordance with an ordinary method by using DNA synthesizer model 380B produced by Applied Biosystems and using the phosphoamidite method (see Tetrahedron Letters (1981), 22 , 1859).
  • PCR can be performed by using DNA Thermal Cycler Model PJ2000 produced by Takara Shuzo, and using Taq DNA polymerase in accordance with a method designated by the supplier.
  • the vector autonomously replicable in cells of E. coli is preferably a plasmid vector which is preferably autonomously replicable in cells of a host, including, for example, pUC19, pUC18, pBR322, pHSG299, pHSG399, pHSG398, and RSF1010.
  • Such a shuttle vector includes the followings. Microorganisms harboring each of vectors and accession numbers in international deposition authorities (in parentheses) are shown. pHC4: Escherichia coli AJ12617 (FERM BP-3532) pAJ655: Escherichia coli AJ11882 (FERM BP-136) Corynebacterium glutamicum SR8201 (ATCC 39135) pAJ1844: Escherichia coli AJ11883 (FERM BP-137) Corynebacterium glutamicum SR8202 (ATCC 39136) pAJ611: Escherichia coli AJ11884 (FERM BP-138) pAJ3148: Corynebacterium glutamicum SR8203 (ATCC 39137) pAJ440: Bacillus subtilis AJ11901 (FERM BP-140)
  • vectors are obtainable from the deposited microorganisms as follows. Cells collected at a logarithmic growth phase were lysed by using lysozyme and SDS, followed by separation from a lysate by centrifugation at 30,000 ⁇ g to obtain a supernatant. To the supernatant, polyethylene glycol is added, followed by fractionation and purification by means of cesium chloride-ethidium bromide equilibrium density gradient centrifugation.
  • E. coli can be transformed by introducing a plasmid in accordance with, for example, a method of D. M. Morrison ( Methods in Enzymology , 68 , 326 (1979)) or a method in which recipient cells are treated with calcium chloride to increase permeability for DNA (Mandel, M. and Higa, A., J. Mol. Biol. , 53 , 159 (1970)).
  • Wild type lysC is obtained when lysC is isolated from an AK wild type strain, while mutant lysC is obtained when lysC is isolated from an AK mutant strain in accordance with the method as described above.
  • nucleotide sequence of a DNA fragment containing wild type lysC is shown in SEQ ID NO: 3 in Sequence Listing.
  • An amino acid sequence of ⁇ -subunit of a wild type AK protein is deduced from the nucleotide sequence, and is shown in SEQ ID NO: 4 in Sequence Listing together with the DNA sequence. Only the amino acid sequence is shown in SEQ ID NO: 5.
  • An amino acid sequence of ⁇ -subunit of the wild type AK protein is deduced from the nucleotide sequence of DNA, and is shown in SEQ ID NO: 6 in Sequence Listing together with the DNA sequence. Only the amino acid sequence is shown in SEQ ID NO: 7.
  • GTG is used as an initiation codon
  • a corresponding amino acid is represented by methionine.
  • this representation refers to methionine, valine, or formylmethionine.
  • the mutant lysC used in the present invention is not specifically limited provided that it codes for AK in which synergistic feedback inhibition by L-lysine and L-threonine is desensitized.
  • the mutant lysC is exemplified by one including mutation in which an amino acid residue corresponding to a 279th alanine residue as counted from the N-terminal is changed into an amino acid residue other than alanine and other than acidic amino acid in the ⁇ -subunit, and an amino acid residue corresponding to a 30th alanine residue from the N-terminal is changed into an amino acid residue other than alanine and other than acidic amino acid in the ⁇ -subunit in the amino acid sequence of the wild type AK.
  • the amino acid sequence of the wild type AK specifically includes the amino acid sequence shown in SEQ ID NO: 5 in Sequence Listing as the ⁇ -subunit, and the amino acid sequence shown in SEQ ID NO: 7 in Sequence Listing as the ⁇ -subunit.
  • amino acid residue other than alanine and other than acidic amino acid include threonine, arginine, cysteine, phenylalanine, proline, serine, tyrosine, and valine residues.
  • the codon corresponding to an amino acid residue to be substituted is not specifically limited for its type provided that it codes for the amino acid residue. It is predicted that the amino acid sequence of wild type AK may slightly differ depending on the difference in bacterial species and bacterial strains. AK's, which have mutation based on, for example, substitution, deletion, or insertion of one or more amino acid residues at one or more positions irrelevant to the enzyme activity as described above, can be also used for the present invention.
  • a DNA coding for AK having the spontaneous mutation can be obtained by isolating a DNA which is hybridizable with, for example, the DNA having a part of the nucleotide sequence shown in SEQ ID NO: 3 under the stringent condition.
  • the condition is exemplified by a condition under which, nucleic acid having high homology, for example, DNA's having homology of not less than 90% are hybridized with each other, and nucleic acids having homology lower than the above are not hybridized with each other, or a condition of a temperature of from a melting out temperature (Tm) of a completely-matched hybrid to (Tm - 30)°C, preferably from Tm to (Tm - 20)°C and a salt concentration corresponding to 1 ⁇ SSC, preferably 0.1 ⁇ SSC.
  • Tm melting out temperature
  • AK's which have artificial mutation based on, for example, substitution, deletion, or insertion of other one or more amino acid residues, can be also used provided that no influence is substantially exerted on the AK activity, and on the desensitization of synergistic feedback inhibition by L-lysine and L-threonine.
  • a DNA coding for AK having the artificial mutation can be obtained by modifying the nucleotide sequence to give substitution, deletion or insertion of a specified site by, for example, site-specific mutagenesis.
  • lysC having the mutation can be obtained by known mutagen treatment.
  • the mutagen treatment includes in vitro treatment of a DNA containing lysC with hydroxylamine or the like, and treatment of microorganism harboring a DNA containing lysC with a mutagen such as ultraviolet irradiation or a mutagenic agent used for ordinary artificial mutagenesis such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or nitric acid.
  • a mutagen such as ultraviolet irradiation or a mutagenic agent used for ordinary artificial mutagenesis such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or nitric acid.
  • NTG N-methyl-N'-nitro-N-nitrosoguanidine
  • a site to which mutation is introduced or in which mutation occurs can be determined by selecting a DNA or a microorganism which codes for or produces AK which has the AK activity and whose amino acid sequence is mutated from the DNA subjected to the mutagen treatment or the microorgan
  • a site of the introduced mutation is not specifically restricted provided that no influence is substantially exerted on the AK activity and on densitization of feedback inhibition.
  • a number of the introduced mutation varies depending on a site or a kind of the mutated amino acid in a steric structure of a protein, and is not specifically restricted provided that no influence is substantially exerted on the AK activity and on densitization of feedback inhibition. The number is usually 1 to 20, preferably 1 to 10.
  • An AJ12691 strain obtained by introducing a mutant lysC plasmid p399AK9B into an AJ12036 strain (FERM BP-734) as a wild type strain of Brevibacterium lactofermentum has been deposited on April 10, 1992 under an accession number of FERM P-12918 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology of Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305 Japan), transferred to international deposition based on the Budapest Treaty on February 10, 1995, and deposited under an accession number of FERM BP-4999.
  • a DNA fragment containing lysA can be prepared from chromosome of a coryneform bacterium by means of PCR.
  • the DNA donor is not specifically limited, however, it is exemplified by Brevibacterium lactofermentum ATCC 13869 strain.
  • lysA forms an operon together with argS (arginyl-tRNA synthase gene), and lysA exists downstream from argS .
  • Expression of lysA is regulated by a promoter existing upstream from argS (see Journal of Bacteriology , Nov. , 7356-7362 (1993)).
  • DNA sequences of these genes are known for Corynebacterium glutamicum (see Molecular Microbiology , 4(11) , 1819-1830 (1990); Molecular and General Genetics , 212 , 112-119 (1988)), on the basis of which DNA primers for PCR can be prepared.
  • DNA primers are specifically exemplified by DNA's of 23-mers respectively having nucleotide sequences shown in SEQ ID NO: 8 in Sequence Listing (corresponding to nucleotide numbers 11 to 33 in a nucleotide sequence described in Molecular Microbiology , 4(11) , 1819-1830 (1990)) and SEQ ID NO: 9 (corresponding to nucleotide numbers 1370 to 1392 in a nucleotide sequence described in Molecular and General Genetics , 212 , 112-119 (1988)).
  • Synthesis of DNA, PCR, and preparation of a plasmid containing obtained lysA can be performed in the same manner as those for lysC described above.
  • Example described later on a DNA fragment containing a promoter, argS , and lysA was used in order to enhance lysA .
  • argS is not essential for the present invention. It is allowable to use a DNA fragment in which lysA is ligated just downstream from a promoter.
  • a nucleotide sequence of a DNA fragment containing argS and lysA , and an amino acid sequence deduced to be encoded by the nucleotide sequence are exemplified in SEQ ID NO: 10.
  • An example of an amino acid sequence encoded by argS is shown in SEQ ID NO: 11, and an example of an amino acid sequence encoded by lysA is shown in SEQ ID NO: 12.
  • the present invention can equivalently use DNA fragments coding for amino acid sequences substantially the same as the amino acid sequence shown in SEQ ID NO: 12, namely amino acid sequences having mutation based on, for example, substitution, deletion, or insertion of one or more amino acids provided that there is no substantial influence on the DDC activity.
  • the lysA having spontaneous or artificial mutation can be obtained in the same manner as those for the DNA coding for AK having mutation which exerts no influence on the AK activity and on the desensitization of synergistic feedback inhibition by L-lysine and L-threonine.
  • a DNA fragment containing ppc can be prepared from chromosome of a coryneform bacterium by means of PCR.
  • the DNA donor is not specifically limited, however, it is exemplified by Brevibacterium lactofermentum ATCC 13869 strain.
  • a DNA sequences of the ppc gene is known for Corynebacterium glutamicum (see O'Regan, M. et al., Gene , 77 , 237-251 (1989)), on the basis of which DNA primers for PCR can be prepared.
  • DNA primers are specifically exemplified by DNA's of 23-mers respectively having nucleotide sequences shown in SEQ ID NOs: 13 and 14 in Sequence Listing. Synthesis of DNA, PCR, and preparation of a plasmid containing obtained ppc can be performed in the same manner as those for lysC described above.
  • a nucleotide sequence of a DNA fragment containing ppc , and an amino acid sequence deduced to be encoded by the nucleotide sequence are shown in SEQ ID NO: 15. Only the amino acid sequence is shown in SEQ ID NO: 16.
  • the present invention can equivalently use DNA fragments coding for amino acid sequences substantially the same as the amino acid sequence shown in SEQ ID NO: 16, namely amino acid sequences having mutation based on, for example, substitution, deletion, or insertion of one or more amino acids provided that there is no substantial influence on the PEPC activity.
  • the ppc having spontaneous or artificial mutation can be obtained in the same manner as those for the DNA coding for AK having mutation which exerts no influence on the AK activity and on the desensitization of synergistic feedback inhibition by L-lysine and L-threonine.
  • the ppc from the coryneform bacteria forms an operon together with gap (glyceraldehyde-3-phosphate dehydrogenase gene), pgk (phosphoglycerate kinase gene) and tpi (triose phosphate isomerase gene), and ppc exists downstream from tpi .
  • gap glycosylaldehyde-3-phosphate dehydrogenase gene
  • pgk phosphoglycerate kinase gene
  • tpi triose phosphate isomerase gene
  • ppc can be amplified together with pgk and tpi by PCR to use a DNA fragment containing p gk , tpi and ppc .
  • a suitable promoter is ligated just upstream from a coding region of PEPC.
  • the promoter includes a promotor of lysC , tac promoter originating from E. coli , and trc promoter.
  • the recombinant DNA comprises a DNA sequence coding for an aspartokinase in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, and a DNA sequence coding for a diaminopimelate decarboxylase, and is autonomously replicable in cells of coryneform bacteria.
  • the recombinant DNA further comprises a DNA sequence coding for a phosphoenolpyruvate carboxylase in addition to the above DNA sequences.
  • the coryneform bacterium of the present invention harbors an aspartokinase (mutant AK) in which feedback inhibition by L-lysine and L-threonine is substantially desensitized, wherein DNA ( lysA ) coding for a diaminopimelate decarboxylase is enhanced.
  • the coryneform bacterium of the present invention is a coryneform bacterium in which DNA ( ppc ) coding for a phosphoenolpyruvate carboxylase is further enhanced.
  • the term "enhance” herein refers to the fact that the intracellular activity of an enzyme encoded by the DNA is raised by, for example, increasing the copy number of a gene, using a strong promoter, using a gene coding for an enzyme having a high specific activity, or combining these means.
  • the coryneform bacterium harboring the mutant AK may be those which produce the mutant aspartokinase as a result of mutation, or those which are transformed by introducing mutant lysC .
  • coryneform bacterium used to introduce the DNA described above include, for example, the following lysine-producing wild type strains:
  • mutant strains having an L-lysine-producing ability derived from the aforementioned strains include, for example, mutant strains having an L-lysine-producing ability derived from the aforementioned strains.
  • Such artificial mutant strains includes the followings: S-(2-aminoethyl)-cysteine (hereinafter abbreviated as "AEC") resistant mutant strains (for example, Brevibacterium lactofermentum AJ11082 (NRRL B-1147), Japanese Patent Publication Nos.
  • mutant strains which require amino acid such as L-homoserine for their growth
  • mutant strains which exhibit resistance to AEC and require amino acids such as L-leucine, L-homoserine, L-proline, L-serine, L-arginine, L-alanine, and L-valine
  • L-lysine-producing mutant strains which exhibit resistance to DL- ⁇ -amino-e-caprolactam, ⁇ -amino-lauryllactam, aspartate-analog, sulfa drug, quinoid, and N-lauroylleucine; L-lysine-producing mutant strains which exhibit resistance to inhibitors of oxyaloacetate decarboxylase or respiratory system enzymes (Japanese Patent Application Laid-open Nos. 50-53588, 50-31093, 52-102498, 53-9394, 53-86089, 55-9783, 55-9759, 56-32995 and 56-39778, and Japanese Patent Publication Nos.
  • L-lysine-producing mutant strains which require inositol or acetic acid (Japanese Patent Application Laid-open Nos. 55-9784 and 56-8692); L-lysine-producing mutant strains which exhibit sensitivity to fluoropyruvic acid or temperature not less than 34°C (Japanese Patent Application Laid-open Nos. 55-9783 and 53-86090); and producing mutant strains belonging to the genus Brevibacterium or Corynebacterium which exhibit resistance to ethylene glycol and produce L-lysine (United States Patent No. 4,411,997).
  • the genes are introduced into the host by using a plasmid vector, transposon or phage vector or the like.
  • a plasmid vector includes, for example, plasmid vectors, pAJ655, pAJ1844, pAJ611, pAJ3148, and pAJ440 described above.
  • transposons derived from coryneform bacteria are described in International Publication Pamphlets of WO02/02627 and WO93/18151, European Patent Publication No.
  • mutant lysC it is not indispensable that the mutant lysC is necessarily enhanced. It is allowable to use those which have mutation on lysC on chromosomal DNA, or in which the mutant lysC is incorporated into chromosomal DNA. Alternatively, the mutant lysC may be introduced by using a plasmid vector. On the other hand, lysA and ppc are preferably enhanced in order to efficiently produce L-lysine.
  • Each of the genes of lysC , lysA , and ppc may be successively introduced into the host by using different vectors respectively. Alternatively, two or three species of the genes may be introduced together by using a single vector. When different vectors are used, the genes may be introduced in any order, however, it is preferred to use vectors which have a stable sharing and harboring mechanism in the host, and which are capable of co-existing with each other.
  • a coryneform bacterium harboring the mutant AK and further comprising enhanced lysA is obtained, for example, by introducing, into a host coryneform bacterium, a recombinant DNA containing mutant lysC , lysA and ppc autonomously replicable in cells of coryneform bacteria.
  • a coryneform bacterium further comprising enhanced ppc in addition to mutant lysC and lysA is obtained, for example, by introducing, into a host coryneform bacterium, a recombinant DNA containing mutant lysC , lysA , and ppc autonomously replicable in cells of coryneform bacteria. Also, a coryneform bacterium comprising enhanced mutant lysC , lysA and ppc is obtained by introducing, into a coryneform bacterium comprising enhanced mutant lysC and lysA , a recombinant DNA containing ppc autonomously replicable in cells of coryneform bacteria.
  • the above-mentioned recombinant DNAs can be obtained, for example, by inserting each of the genes participating in L-lysine biosynthesis into a vector such as plasmid vector, transposon or phage vector as described above.
  • the recombinant DNA can be introduced into the host in accordance with an electric pulse method (Sugimoto et al., Japanese Patent Application Laid-open No. 2-207791).
  • Amplification of a gene using transposon can be performed by introducing a plasmid which carrying a transposon into the host cell and inducing transposition of the transposon.
  • L-Lysine can be efficiently produced by cultivating, in an appropriate medium, the coryneform bacterium comprising the enhanced genes for L-lysine biosynthesis as described above, to allow L-lysine to be produced and accumulated in a culture of the bacterium, and collecting L-lysine from the culture.
  • the medium to be used is exemplified by an ordinary medium containing a carbon source, a nitrogen source, inorganic ions, and optionally other organic components.
  • the carbon source it is possible to use sugars such as glucose, fructose, sucrose, molasses, and starch hydrolysate; and organic acids such as fumaric acid, citric acid, and succinic acid.
  • sugars such as glucose, fructose, sucrose, molasses, and starch hydrolysate
  • organic acids such as fumaric acid, citric acid, and succinic acid.
  • the nitrogen source it is possible to use inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate; organic nitrogen such as soybean hydrolysate; ammonia gas; and aqueous ammonia.
  • inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate
  • organic nitrogen such as soybean hydrolysate
  • ammonia gas such as soybean hydrolysate
  • aqueous ammonia aqueous ammonia.
  • organic trace nutrient sources it is desirable to contain required substances such as vitamin B 1 and L-homoserine or yeast extract or the like in appropriate amounts.
  • required substances such as vitamin B 1 and L-homoserine or yeast extract or the like in appropriate amounts.
  • potassium phosphate, magnesium sulfate, iron ion, manganese ion and so on are added in small amounts, if necessary.
  • Cultivation is preferably carried out under an aerobic condition for about 30 to 90 hours.
  • the cultivation temperature is preferably controlled at 25°C to 37°C, and pH is preferably controlled at 5 to 8 during cultivation.
  • Inorganic or organic, acidic or alkaline substances, or ammonia gas or the like can be used for pH adjustment.
  • L-lysine can be collected from a culture by combining an ordinary ion exchange resin method, a precipitation method, and other known methods.
  • Example 1 Preparation of Wild Type lysC Gene and Mutant lysC Gene from Brevibacterium lactofermentum
  • a strain of Brevibacterium lactofermentum ATCC 13869, and an L-lysine-producing mutant strain AJ3445 (FERM P-1944) obtained from the ATCC 13869 strain by a mutation treatment were used as chromosomal DNA donors.
  • the AJ3445 strain had been subjected to mutation so that lysC was changed to involve substantial desensitization from concerted inhibition by lysine and threonine (Journal of Biochemistry , 68 , 701-710 (1970)).
  • a DNA fragment containing lysC was amplified from chromosomal DNA in accordance with the PCR method (polymerase chain reaction; see White, T. J. et al., Trends Genet. , 5 , 185 (1989)).
  • DNA primers used for amplification single strand DNA's of 23-mer and 21-mer having nucleotide sequences shown in SEQ ID NOs: 1 and 2 were synthesized in order to amplify a region of about 1,643 bp coding for LysC on the basis of a sequence known for Corynebacterium glutamicum (see Molecular Microbiology (1991), 5(5) , 1197-1204; and Mol. Gen. Genet.
  • DNA was synthesized in accordance with an ordinary method by using DNA synthesizer model 380B produced by Applied Biosystems and using the phosphoamidite method (see Tetrahedron Letters (1981), 22 , 1859).
  • the gene was amplified by PCR by using DNA Thermal Cycler Model PJ2000 produced by Takara Shuzo, and using Taq DNA polymerase in accordance with a method designated by the supplier.
  • An amplified gene fragment of 1,643 kb was confirmed by agarose gel electrophoresis. After that, the fragment excised from the gel was purified in accordance with an ordinary method, and it was digested with restriction enzymes Nru I (produced by Takara Shuzo) and Eco RI (produced by Takara Shuzo).
  • pHSG399 (see Takeshita, S. et al., Gene (1987), 61 , 63-74) was used as a cloning vector for the gene fragment.
  • pHSG399 was digested with restriction enzymes Sma I (produced by Takara Shuzo) and Eco RI, and it was ligated with the amplified lysC fragment.
  • DNA was ligated by using DNA ligation kit (produced by Takara Shuzo) in accordance with a designated method.
  • DNA ligation kit produced by Takara Shuzo
  • a plasmid comprising lysC from ATCC 13869 (wild type strain) was designated as p399AKY
  • a plasmid comprising lysC from AJ3463 (L-lysine-producing bacterium) was designated as p399AK9.
  • a DNA fragment (hereinafter referred to as "Brevi.-ori") having an ability to make a plasmid autonomously replicable in bacteria belonging to the genus Corynebacterium was introduced into p399AKY and p399AK9 respectively to prepare plasmids carrying lysC ' autonomously replicable in bacteria belonging to the genus Corynebacterium .
  • Brevi.-ori was prepared from a plasmid vector pHK4 containing Brevi.-ori and autonomously replicable in cells of both Escherichia coli and bacteria belonging to the genus Corynebacterium .
  • pHK4 was constructed by digesting pHC4 with Kpn I (produced by Takara Shuzo) and Bam HI (produced by Takara Shuzo), extracting a Brevi.-ori fragment, and ligating it with pHSG298 having been also digested with Kpn I and Bam HI (see Japanese Patent Application Laid-open No. 5-7491). pHK4 gives kanamycin resistance to a host.
  • Escherichia coli harboring pHK4 was designated as Escherichia coli AJ13136, and deposited on August 1, 1995 under an accession number of FERM BP-5186 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology of Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305 Japan).
  • pHK4 was digested with restriction enzymes Kpn I and Bam HI, and cleaved edges were blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Bam HI linker (produced by Takara Shuzo) was ligated to make modification so that the DNA fragment corresponding to the Brevi.-ori portion might be excised from pHK4 by digestion with only Bam HI.
  • This plasmid was digested with Bam HI, and the generated Brevi.-ori DNA fragment was ligated with p399AKY and p399AK9 having been also digested with Bam HI respectively to prepare plasmids each containing the lysC gene autonomously replicable in bacteria belonging to the genus Corynebacterium .
  • p399AKYB A plasmid containing the wild type lysC gene originating from p399AKY was designated as p399AKYB, and a plasmid containing the mutant lysC gene originating from p399AK9 was designated as p399AK9B.
  • the process of construction of p399AK9B and p399AKYB is shown in Fig. 1.
  • a strain AJ12691 obtained by introducing the mutant lysC plasmid p399AK9B into a wild type strain of Brevibacterium lactofermentum (AJ12036 strain, FERM BP-734) was deposited on April 10, 1992 under an accession number of FERM P-12918 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology of Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305 Japan), transferred to international deposition based on the Budapest Treaty on February 10, 1995, and deposited under an accession number of FERM BP-4 999.
  • the plasmid p399AKY containing the wild type lysC and the plasmid p399AK9 containing the mutant lysC were prepared from the respective transformants to determine nucleotide sequences of the wild type and mutant lysC's . Nucleotide sequence determination was performed in accordance with a method of Sanger et al. (for example, F. Sanger et al., Proc. Natl. Acad. Sci. , 74 , 5463 (1977)).
  • nucleotide sequence of wild type lysC encoded by p399AKY is shown in SEQ ID NO: 3 in Sequence Listing.
  • nucleotide sequence of mutant lysC encoded by p399AK9 had only mutation of one nucleotide such that 1051st G was changed into A in SEQ ID NO: 3 as compared with wild type lysC .
  • lysC of Corynebacterium glutamicum has two subunits ( ⁇ , ⁇ ) encoded in an identical reading frame on an identical DNA strand (see Kalinowski, J. et al., Molecular Microbiology (1991) 5(5) , 1197-1204). Judging from homology, it is assumed that the gene sequenced herein also has two subunits ( ⁇ , ⁇ ) encoded in an identical reading frame on an identical DNA strand.
  • An amino acid sequence of the ⁇ -subunit of the wild type AK protein deduced from the nucleotide sequence of DNA is shown in SEQ ID NO: 4 together with the DNA sequence. Only the amino acid sequence is shown in SEQ ID NO: 5.
  • An amino acid sequence of the ⁇ -subunit of the wild type AK protein deduced from the nucleotide sequence of DNA is shown in SEQ ID NO: 6 together with DNA sequence. Only the amino acid sequence is shown in SEQ ID NO: 7.
  • GTG is used as an initiation codon
  • a corresponding amino acid is represented by methionine. However, this representation refers to methionine, valine, or formylmethionine.
  • mutation on the sequence of mutant lysC means occurrence of amino acid residue substitution such that a 279th alanine residue of the ⁇ -subunit is changed into a threonine residue, and a 30th alanine residue of the ⁇ -subunit is changed into a threonine residue in the amino acid sequence of the wild type AK protein (SEQ ID NOs: 5, 7).
  • a wild type strain of Brevibacterium lactofermentum ATCC 13869 was used as a chromosomal DNA donor.
  • Chromosomal DNA was prepared from the ATCC 13869 strain in accordance with an ordinary method.
  • a DNA fragment containing argS , lysA , and a promoter of an operon containing them was amplified from the chromosomal DNA in accordance with PCR.
  • DNA primers used for amplification synthetic DNA's of 23-mers having nucleotide sequences shown in SEQ ID NOs: 8 and 9 in Sequence Listing respectively were used in order to amplify a region of about 3.6 kb coding for arginyl-tRNA synthase and DDC on the basis of a sequence known for Corynebacterium glutamicum (see Molecular Microbiology , 4(11) , 1819-1830 (1990); Molecular and General Genetics , 212 , 112-119 (1988)). Synthesis of DNA and PCR were performed in the same manner as described in Example 1. pHSG399 was used as a cloning vector for the amplified gene fragment of 3,579 bp.
  • pHSG399 was digested with a restriction enzyme Sma I (produced by Takara Shuzo), and was ligated with the DNA fragment containing amplified lysA .
  • Sma I produced by Takara Shuzo
  • a DNA fragment containing lysA was extracted by digesting p399LYSA with Kpn I (produced by Takara Shuzo) and Bam HI (produced by Takara Shuzo). This DNA fragment was ligated with pHSG299 having been digested with Kpn I and Bam HI. An obtained plasmid was designated as p299LYSA. The process of construction of p299LYSA is shown in Fig. 2.
  • Brevi.-ori was introduced into the obtained p299LYSA to construct a plasmid carrying lysA autonomously replicable in coryneform bacteria.
  • pHK4 was digested with restriction enzymes Kpn I and Bam HI, and cleaved edges were blunt-ended.
  • Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Kpn I linker (produced by Takara Shuzo) was ligated to make modification so that the DNA fragment corresponding to the Brevi.-ori portion might be excised from pHK4 by digestion with only Kpn I.
  • This plasmid was digested with Kpn I, and the generated Brevi.-ori DNA fragment was ligated with p299LYSA having been also digested with Kpn I to prepare a plasmid containing lysA autonomously replicable in coryneform bacteria.
  • the prepared plasmid was designated as pLYSAB.
  • the process of construction of pLYSAB is shown in Fig. 3.
  • Plasmid DNA of p299LYSA was prepared, and its nucleotide sequence was determined in the same manner as described in Example 1. A determined nucleotide sequence and an amino acid sequence deduced to be encoded by the nucleotide sequence are shown in SEQ ID NO: 10. Concerning the nucleotide sequence, an amino acid sequence encoded by argS and an amino acid sequence encoded by lysA are shown in SEQ ID NOs: 11 and 12, respectively.
  • a wild type strain of Brevibacterium lactofermentum ATCC 13869 was used as a chromosomal DNA donor.
  • Chromosomal DNA was prepared from the ATCC 13869 strain in accordance with an ordinary method.
  • a DNA fragment containing ppc was amplified from the chromosomal DNA in accordance with PCR.
  • DNA primers used for amplification synthetic DNA's of 23-mers having nucleotide sequences shown in SEQ ID NOs: 13 and 14 in Sequence Listing respectively were used in order to amplify a region of about 3.3 kb coding for PEPC on the basis of a sequence known for Corynebacterium glutamicum (see O'Regan, M. et al., Gene , 77 , 237-251 (1989)). Synthesis of DNA and PCR were performed in the same manner as described in Example 1.
  • An amplified gene fragment of about 3,300 bp was confirmed by agarose gel electrophoresis, and then the fragment extracted from the gel was purified by an ordinary method and digested with a restriction enzyme Sal I (produced by Takara Shuzo). pHSG399 was used as a cloning vector for ppc . pHSG399 was digested with a restriction enzyme Sal I (produced by Takara Shuzo), and was ligated with the DNA fragment containing amplified ppc .
  • the pPCF obtained as described in the above was digested with a restriction enzyme Dra I (produced by Takara Shuzo). After a DNA fragment of about 150 bp upstream of the PEPC structural gene was removed, self-ligation was effected to obtain a plasmid pPCFds.
  • pPCFds was digested with a restriction enzyme Sal I (produced by Takara Shuzo), and cleaved edges were blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method.
  • p399AKYB containing wild type lysC obtained in Example 1 was digested with restriction enzymes ApaLI and Pst I (both produced by Takara Shuzo), and cleaved edges were blunt-ended in the same manner as above.
  • a smaller fragment among the obtained two DNA fragments contains Brevi.-ori and a promoter of lysC .
  • This fragment was ligated with the above-mentioned fragment obtained by digesting pPCFds with Sal I and blunt-ended by using DNA Ligation kit (produced by Takara Shuzo).
  • a DNA in a ligation solution was introduced into Brevibacterium lactofermentum ATCC 13869 in accordance with an electric pulse method (Sugimoto et al., Japanese Patent Application Laid-open No. 2-207791). Transformants were selected on a complete medium containing 5 ⁇ g/ml of chloramphenicol. Plasmid DNA was collected from the transformants, and digested with Eco RI to obtain a plasmid in which the lysC promoter was ligated with the ppc structural gene in normal orientation. The obtained plasmid was designated as pAKPFds. The process of construction of pAKPFds is shown in Fig. 4. The ppc ligated with the lysC promoter is hereinafter referred to as "wild type high expression ppc ".
  • the wild type high expression ppc obtained in the above was amplified by PCR to insert it into a vector having a replication origin autonomously replicable in coryneform bacteria other than Brevi.-ori.
  • DNA primers an oligonucleotide corresponding to the lysC promoter portion (SEQ ID NO: 7), which was synthesized on the basis of a sequence of lysC known for Corynebacterium glutamicum (see Molecular Microbiology , 5(5) , 1197-1204 (1991); Mol. Gen. Genet.
  • pVK7 was constructed by ligating pHSG299, a vector for E. coli (Km r ; Takeshita, S. et al., Gene , 61 , 63-74 (1987)) with pAM330, a cryptic plasmid for Brevibacterium lactofermentum as described below.
  • pHSG299 was digested with a restriction enzyme resulting one cleavage site, Ava II (produced by Takara Shuzo), blunt-ended by using T4 DNA polymerase, and ligated with pAM330 having been digested with Hind III (produced by Takara Shuzo) and blunt-ended by using T4 DNA polymerase.
  • Ava II produced by Takara Shuzo
  • pAM330 having been digested with Hind III (produced by Takara Shuzo) and blunt-ended by using T4 DNA polymerase.
  • the two obtained plasmids were designated as pVK6 and pVK7, and pVK7 was used for the following experiments.
  • pVK7 is autonomously . replicable in both of E. coli and Brevibacterium lactofermentum and has a multiple cloning site originating from pHSG299 and lacZ' .
  • the process of construction of pVK6 and pVK7 is shown in Fig. 5.
  • Example 4 Preparation of plasmid comprising combination of mutant lysC and lysA
  • a plasmid containing mutant lysC , lysA , and a replication origin for coryneform bacteria was prepared from plasmid p399AK9B containing mutant lysC and Brevi.-ori and plasmid p299LYSA containing lysA .
  • p299LYSA was digested with restriction enzymes Bam HI and Kpn I (both produced by Takara Shuzo) and blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method.
  • the obtained DNA fragment was ligated with p399AK9B having been digested with Sal I and blunt-ended.
  • pCL The process of construction of pCL is shown in Fig. 7.
  • dap A dihydrodipicolinate synthase gene
  • dapB dihydrodipicolinate reductase gene
  • ddh diaminopimelate dehydrogenase gene
  • a wild type strain of Brevibacterium lactofermentum ATCC 13869 was used as a chromosomal DNA donor.
  • Chromosomal DNA was prepared from the ATCC 13869 strain in accordance with an ordinary method.
  • a DNA fragment containing dapA was amplified from the chromosomal DNA in accordance with PCR.
  • DNA primers used for amplification DNA's of 23-mers having nucleotide sequences shown in SEQ ID NOs: 21 and 22 in Sequence Listing respectively were synthesized in order to amplify a region of about 1.5 kb coding for DDPS on the basis of a sequence known for Corynebacterium glutamicum (see Nucleic Acids Research , 18(21) , 6421 (1990); EMBL accession No. X53993). Synthesis of DNA and PCR were performed in the same manner as described in Example 1.
  • pCR1000 (produced by Invitrogen, see Bio/Technology , 9 , 657-663 (1991)) was used as a cloning vector for the amplified gene fragment of 1,411 bp, and was ligated with the amplified dapA fragment. Ligation of DNA was performed by using DNA ligation kit (produced by Takara Shuzo) in accordance with_a designated-method. Thus a _ plasmid was constructed, in which the dapA fragment of 1,411 bp amplified from chromosome of Brevibacterium lactofermentum was ligated with pCR1000. The plasmid obtained as described above, which had dapA originating from ATCC 13869, was designated as pCRDAPA.
  • a transformant strain AJ13106 obtained by introducing pCRDAPA into E. coli JM109 strain has been internationally deposited since May 26, 1995 under an accession number of FERM BP-5113 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology of Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305 Japan) based on the Budapest Treaty.
  • Brevi.-ori was introduced into the prepared pCRDAPA to construct a plasmid carrying dapA autonomously replicable in coryneform bacteria.
  • pHK4 was digested with restriction enzymes Kpn I and Bam HI (produced by Takara Shuzo), and cleaved edges were blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Sma I linker (produced by Takara Shuzo) was ligated to make modification so that the DNA fragment corresponding to the Brevi.-ori portion might be excised from pHK4 by digestion with only Sma I.
  • This plasmid was digested with SmaI , and the generated Brevi.-ori DNA fragment was ligated with pCRDAPA having been also digested with Sma I to prepare a plasmid containing dapA autonomously replicable in coryneform bacteria.
  • This plasmid was designated as pDPSB.
  • the process of construction of pDPSB(Km r ) is shown in Fig. 8.
  • a wild type strain of Brevibacterium lactofermentum ATCC 13869 was used as a chromosomal DNA donor. Chromosomal DNA was prepared from the ATCC 13869 strain in accordance with an ordinary method. A DNA fragment containing dapB was amplified from the chromosomal DNA in accordance with PCR.
  • DNA primers used for amplification DNA's of 23-mers having nucleotide sequences depicted in SEQ ID NOs: 19 and 20 in Sequence Listing respectively were synthesized in order to amplify a region of about 2.0 kb coding for DDPR on the basis of a sequence known for Brevibacterium lactofermentum (see Journal of Bacteriology , 175(9) , 2743-2749 (1993)). Synthesis of DNA and PCR were performed in the same manner as described in Example 1. pCR-Script (produced by Invitrogen) was used as a cloning vector for the amplified gene fragment of 2,001 bp, and was ligated with the amplified dapB fragment.
  • a plasmid was constructed, in which the dapB fragment of 2,001 bp amplified from chromosome of Brevibacterium lactofermentum was ligated with pCR-Script.
  • a transformant strain AJ13107 obtained by introducing pCRDAPB into E. coli JM109 strain has been internationally deposited since May 26, 1995 under an accession number of FERM BP-5114 in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology of Ministry of International Trade and Industry (1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305 Japan) based on the Budapest Treaty.
  • a fragment of 1,101 bp containing a structural gene of DDPR was extracted by digesting pCRDAPB with Eco RV and Sph I. This fragment was ligated with pHSG399 having been digested with Hin cII and Sph I to prepare a plasmid. The prepared plasmid was designated as p399DPR.
  • Brevi.-ori was introduced into the prepared p399DPR to construct a plasmid carrying dapB autonomously replicable in coryneform bacteria.
  • pHK4 was digested with a restriction enzyme Kpn I (produced by Takara Shuzo), and cleaved edges were blunt-ended.
  • Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Bam HI linker (produced by Takara Shuzo) was ligated to make modification so that the DNA fragment corresponding to the Brevi.-ori portion might be excised from pHK4 by digestion with only Bam HI.
  • This plasmid was digested with Bam HI, and the generated Brevi.-ori DNA fragment was ligated with p399DPR having been also digested with Bam HI to prepare a plasmid containing dapB autonomously replicable in coryneform bacteria.
  • the prepared plasmid was designated as pDPRB.
  • the process of construction of pDPRB is shown in Fig. 9.
  • a ddh gene was obtained by amplifying the ddh gene from chromosomal DNA of Brevibacterium lactofermentum ATCC 13869 in accordance with the PCR method by using two oligonucleotide primers (SEQ ID NOs: 23, 24)1 prepared on the basis of a known nucleotide sequence of a ddh gene of Corynebacterium glutamicum (Ishino, S. et al., Nucleic Acids Res. , 15 , 3917 (1987)). An obtained amplified DNA fragment was digested with Eco T22I and Ava I, and cleaved edges were blunt-ended. After that, the fragment was inserted into a Sma I site of pMW119 to obtain a plasmid pDDH.
  • pODH was digested with Sal I and Eco RI, followed by blunt end formation. After that, an obtained fragment was ligated with pUC18 having been digested with Sma I. A plasmid thus obtained was designated as pUC18DDH.
  • Brevi.-ori was introduced into pUC18DDH to construct a plasmid carrying ddh autonomously replicable in coryneform bacteria.
  • pHK4 was digested with restriction enzymes Kon I and Bam HI, and cleaved edges were blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Pst I linker (produced by Takara Shuzo) was ligated so that it was inserted into a Pst I site of pHSG299.
  • a plasmid constructed as described above was designated as pPK4.
  • pUC18DDH was digested with Xba I and Kpn I, and a generated fragment was ligated with pPK4 having been digested with Kpn I and Xba I.
  • pPK4D This plasmid was designated as pPK4D.
  • the process of construction of pPK4D is shown in Fig. 10.
  • Comparative Example 2 Construction of plasmid Comprising Combination of Mutant lysC, and dapA, dapB or ddh
  • a plasmid comprising mutant lysC , dapA , and replication origin of coryneform bacteria was constructed from the plasmid pCRDAPA comprising dapA and the plasmid p399AK9B comprising mutant lysC and Brevi.-ori.
  • p399AK9B was completely digested with Sal I, and then it was blunt-ended.
  • An Eco RI linker was ligated thereto to construct a plasmid in which the Sal I site was modified into an Eco RI site.
  • the obtained plasmid was designated as p399AK9BSE.
  • the mutant lysC and Brevi.-ori were excised as one fragment by partially digesting p399AK9BSE with Eco RI.
  • pCRCAB This fragment was ligated with pCRDAPA having been digested with Eco RI.
  • An obtained plasmid was designated as pCRCAB.
  • This plasmid is autonomously replicable in E. coli and coryneform bacteria, and it gives kanamycin resistance to a host, the plasmid comprising a combination of mutant lysC and dapA .
  • the process of construction of pCRCAB is shown in Fig. 11.
  • a plasmid comprising mutant lysC and daoB was constructed from the plasmid p399AK9 having mutant lysC and the plasmid p399DPR having dapB .
  • a fragment of 1,101 bp containing a structural gene of DDPR was extracted by digesting p399DPR with Eco RV and Sph I. This fragment was ligated with p399AK9 having been digested with Sal I and then blunt-ended and having been further digested with Sph I to construct a plasmid comprising a combination of mutant lysC and dapB .
  • This plasmid was designated as p399AKDDPR.
  • Brevi.-ori was introduced into the obtained p399AKDDPR.
  • the plasmid pHK4 containing Brevi.-ori was digested with a restriction enzyme Kpn I (produced by Takara Shuzo), and cleaved edges were blunt-ended. Blunt end formation was performed by using DNA Blunting kit (produced by Takara Shuzo) in accordance with a designated method. After the blunt end formation, a phosphorylated Bam HI linker (produced by Takara Shuzo) was ligated to make modification so that the DNA fragment corresponding to the Brevi.-ori portion might be excised from pHK4 by digestion with only Bam HI.
  • This plasmid was digested with Bam BI, and the generated Brevi.-ori DNA fragment was ligated with p399AKDDPR having been also digested with Bam HI to construct a plasmid containing mutant lysC and dapB autonomously replicable in coryneform bacteria.
  • the constructed plasmid was designated as pCB.
  • the process of construction of pCB is shown in Fig. 12.
  • a plasmid containing mutant lysC , ddh , and a replication origin for coryneform bacteria was prepared from plasmid pUC18DDH containing ddh and plasmid p399AK9B containing mutant lysC and Brevi.-ori.
  • pUC18DDH was digested with a restriction enzyme Eco RI (produced by Takara Shuzo), blunt-ended and ligated with a Sal I polylinker at a terminal thereof to change Eco RI site to Sal I site.
  • the obtained plasmid was digested with Sal I to obtain a DNA fragment containing ddh .
  • p399AK9B was digested with a restriction enzyme Sal I and ligated with the DNA fragment containing ddh .
  • pCD plasmid containing mutant lysC , ddh and Brevi.-ori autonomously replicable in coryneform bacteria
  • the plasmids comprising the genes for L-lysine biosynthesis constructed as described above, namely p399AK9B(Cm r ), pLYSAB(Cm r ) , pPwm(Km r ) , pCRCAB(Km r ) , pCB(Cm r ) , pCD(Cm r ), and pCL(Cm r ) were introduced into an L-lysine-producing bacterium AJ11082 (NRRL B-11470) of Brevibacterium lactofermentum respectively. AJ11082 strain has a property of AEC resistance.
  • the plasmids were introduced in accordance with an electric pulse method (Sugimoto et al., Japanese Patent Application Laid-open No. 2-207791). Transformants were selected based on drug resistance markers possessed by the respective plasmids. Transformants were selected or a complete medium containing 5 ⁇ g/ml of chloramphenicol 1 when a plasmid comprising a chloramphenicol resistance gene was introduced, or transformants were selected on a complete medium containing 25 ⁇ g/ml of kanamycin when a plasmid comprising a kanamycin resistance gene was introduced.
  • Each of the transformants obtained in Example 5 was cultivated in an L-lysine-producing medium to evaluate its L-lysine productivity.
  • the L-lysine-producing medium had the following composition.
  • lysC * represents mutant lysC .
  • mutant lysC , lysA , or ppc was enhanced singly, or when mutant lysC was enhanced in combination with dapA or ddh , the amount of produced L-lysine was larger than or equivalent to that produced by the parent strain after 72 hours of cultivation, however, the amount of produced L-lysine was smaller than that produced by the parent strain after 40 hours of cultivation. Namely, the L-lysine-producing speed was lowered in cultivation for a short period. Similarly, when mutant lysC and ddh were enhanced in combination, the amount of produced L-lysine was smaller than that produced by the parent strain after 40 hours and 72 hours of cultivation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
EP97121444A 1996-12-05 1997-12-05 Method for producing L-lysine Expired - Lifetime EP0857784B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP325658/96 1996-12-05
JP32565896 1996-12-05
JP32565896A JP4075087B2 (ja) 1996-12-05 1996-12-05 Ｌ−リジンの製造法

Publications (3)

Publication Number Publication Date
EP0857784A2 EP0857784A2 (en) 1998-08-12
EP0857784A3 EP0857784A3 (en) 2002-10-16
EP0857784B1 true EP0857784B1 (en) 2006-09-20

Family

ID=18179283

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97121444A Expired - Lifetime EP0857784B1 (en) 1996-12-05 1997-12-05 Method for producing L-lysine

Country Status (11)

Country Link
US (1) US6221636B1 (pt)
EP (1) EP0857784B1 (pt)
JP (1) JP4075087B2 (pt)
CN (1) CN1161470C (pt)
BR (1) BRPI9706058B1 (pt)
DE (1) DE69736699T2 (pt)
DK (1) DK0857784T3 (pt)
ES (1) ES2273356T3 (pt)
HU (1) HU224409B1 (pt)
PL (1) PL190206B1 (pt)
SK (1) SK285146B6 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0857784A2 (en) 1996-12-05 1998-08-12 Ajinomoto Co., Inc. Method for producing L-lysine

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003135066A (ja) * 1999-03-19 2003-05-13 Ajinomoto Co Inc Ｌ−リジンの製造法
WO2000056859A1 (fr) * 1999-03-19 2000-09-28 Ajinomoto Co., Inc. Procede de production des l-aminoacides
MXPA01010151A (es) 1999-04-09 2002-06-21 Ajinomoto Kk Bacterianas que producen l-aminoacido y procedimiento para producir l-aminoacido.
US20030049804A1 (en) 1999-06-25 2003-03-13 Markus Pompejus Corynebacterium glutamicum genes encoding metabolic pathway proteins
CA2377488A1 (en) * 1999-06-29 2001-01-04 Archer-Daniels-Midland Company Regulation of carbon assimilation
US6599732B1 (en) 1999-06-29 2003-07-29 Archer-Daniels-Midland Company Regulation of carbon assimilation
JP2003180348A (ja) * 1999-07-02 2003-07-02 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
JP2003180355A (ja) * 1999-07-02 2003-07-02 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
CN1298854C (zh) 1999-07-02 2007-02-07 味之素株式会社 编码蔗糖pts酶ⅱ的dna
JP2003144160A (ja) * 1999-07-02 2003-05-20 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
JP2003144161A (ja) * 1999-07-02 2003-05-20 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
JP2003169674A (ja) * 1999-07-02 2003-06-17 Ajinomoto Co Inc Ｌ−リジンの製造法
TW200734459A (en) 1999-10-04 2007-09-16 Ajinomoto Kk Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria
AU2223601A (en) * 1999-12-24 2001-07-09 Ajinomoto Co., Inc. Process for producing l-amino acid and novel gene
US6927046B1 (en) 1999-12-30 2005-08-09 Archer-Daniels-Midland Company Increased lysine production by gene amplification using coryneform bacteria
BRPI0017148B1 (pt) * 2000-03-09 2016-03-01 Basf Aktiengesellschfat vetor, célula hospedeira recombinante, e, método para produzir um produto químico fino
KR100397423B1 (ko) * 2001-02-13 2003-09-13 씨제이 주식회사 Ｌ-쓰레오닌의 제조방법
US7368266B2 (en) 2001-02-13 2008-05-06 Cj Corporation Method for L-threonine production
US20050255568A1 (en) * 2003-05-30 2005-11-17 Bailey Richard B Methods and compositions for amino acid production
DE102005032429A1 (de) 2005-01-19 2006-07-20 Degussa Ag Allele des mqo-Gens aus coryneformen Bakterien
DE102005013676A1 (de) 2005-03-24 2006-09-28 Degussa Ag Allele des zwf-Gens aus coryneformen Bakterien
DE102005023829A1 (de) 2005-05-24 2006-11-30 Degussa Ag Allele des opcA-Gens aus coryneformen Bakterien
JP2009118740A (ja) 2006-03-03 2009-06-04 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
EP1881076A1 (en) * 2006-07-17 2008-01-23 Evonik Degussa GmbH Method for producing L-amino acids
EP2066782A4 (en) 2006-09-15 2010-02-03 Cj Cheiljedang Corp CORYNEBACTERIA WITH IMPROVED L-LYSINE PRODUCTIVITY AND METHOD FOR THE PREPARATION OF L-LYSINE THEREWITH
KR100838038B1 (ko) * 2006-12-29 2008-06-12 씨제이제일제당 (주) Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용한 ｌ-라이신 생산 방법
KR100838035B1 (ko) * 2006-12-29 2008-06-12 씨제이제일제당 (주) Ｌ-라이신 생산능이 향상된 코리네박테리움 속 미생물 및그를 이용한 ｌ-라이신 생산 방법
KR100830826B1 (ko) * 2007-01-24 2008-05-19 씨제이제일제당 (주) 코리네박테리아를 이용하여 글리세롤을 포함한탄소원으로부터 발효산물을 생산하는 방법
JP2010226956A (ja) * 2007-07-23 2010-10-14 Ajinomoto Co Inc Ｌ−リジンの製造法
EP2248906A4 (en) 2008-01-23 2012-07-11 Ajinomoto Kk PROCESS FOR THE PREPARATION OF L-AMINO ACID
KR100930203B1 (ko) 2008-01-28 2009-12-07 씨제이제일제당 (주) 개량된 프로모터 및 이를 이용한 ｌ-라이신의 생산 방법
KR100987281B1 (ko) 2008-01-31 2010-10-12 씨제이제일제당 (주) 개량된 프로모터 및 이를 이용한 ｌ-라이신의 생산 방법
KR101126041B1 (ko) * 2008-04-10 2012-03-19 씨제이제일제당 (주) 트랜스포존을 이용한 형질전환용 벡터, 상기 벡터로형질전환된 미생물 및 이를 이용한 ｌ-라이신 생산방법
US8932861B2 (en) 2008-04-10 2015-01-13 Cj Cheiljedang Corporation Transformation vector comprising transposon, microorganisms transformed with the vector, and method for producing L-lysine using the microorganism
JP2010142200A (ja) 2008-12-22 2010-07-01 Ajinomoto Co Inc Ｌ−リジンの製造法
JPWO2011013707A1 (ja) 2009-07-29 2013-01-10 味の素株式会社 Ｌ−アミノ酸の製造法
JP2012196144A (ja) 2009-08-03 2012-10-18 Ajinomoto Co Inc ビブリオ属細菌を用いたｌ−リジンの製造法
JP2012223091A (ja) 2009-08-25 2012-11-15 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
KR101226384B1 (ko) * 2010-03-05 2013-01-25 씨제이제일제당 (주) 개량된 프로모터 및 이를 이용한 ｌ-라이신의 생산 방법
KR101512432B1 (ko) * 2010-06-15 2015-04-16 백광산업 주식회사 미생물을 이용한 아스파테이트 계열 아미노산의 생산방법
EP2479279A1 (de) 2011-01-20 2012-07-25 Evonik Degussa GmbH Verfahren zur fermentativen Herstellung schwefelhaltiger Aminosäuren
IN2014MN01298A (pt) 2011-12-21 2015-07-03 Cj Cheiljedang Corp
EP2628792A1 (de) 2012-02-17 2013-08-21 Evonik Industries AG Zelle mit verringerter ppGppase-Aktivität
EP2700715B1 (de) 2012-08-20 2018-07-25 Evonik Degussa GmbH Verfahren zur fermentativen Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae
EP2940143B1 (de) 2014-04-30 2020-02-05 Evonik Operations GmbH Verfahren zur Produktion von L-Aminosäuren unter Verwendung eines alkaliphilen Bakteriums
EP2940039A1 (de) 2014-04-30 2015-11-04 Evonik Degussa GmbH Verfahren zur Produktion von L-Aminosäuren in Corynebakterien unter Verwendung eines Glycin spaltenden Systems
DE102014208199A1 (de) 2014-04-30 2015-11-05 Evonik Degussa Gmbh Verfahren zur Produktion von L-Aminosäuren unter Verwendung eines alkaliphilen Bakteriums
CN108291243A (zh) 2015-11-27 2018-07-17 赢创德固赛有限公司 生产l-甲硫氨酸的方法
ES2939979T3 (es) 2016-09-01 2023-04-28 Ningxia Eppen Biotech Co Ltd Corynebacterium para producir L-lisina por fermentación
KR102011994B1 (ko) * 2017-06-30 2019-08-20 씨제이제일제당 주식회사 신규한 아스파토키나제 변이체 및 이를 이용한 l-아미노산의 제조방법
WO2020051420A1 (en) * 2018-09-07 2020-03-12 Archer Daniels Midland Company Engineered strains of corynebacteria
CN110804602B (zh) * 2019-11-18 2021-01-29 江南大学 一种L-天冬氨酸β-脱羧酶突变体及其应用
CN114292315B (zh) * 2021-12-31 2024-09-06 宁夏伊品生物科技股份有限公司 ppc突变体及其在制备L-缬氨酸中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861722A (en) * 1983-08-24 1989-08-29 Ajinomoto Company, Inc. Coryneform bacteria carrying recombinant plasmids and their use in the fermentative production of L-lysine
JPH0746994B2 (ja) * 1984-10-04 1995-05-24 味の素株式会社 発酵法によるｌ−アミノ酸の製造法
GB2223754B (en) 1988-09-12 1992-07-22 Degussa Dna encoding phosphoenolpyruvate carboxylase
DE3908201A1 (de) 1989-03-14 1990-09-27 Degussa Verfahren zur fermentativen herstellung von l-lysin
JP3473042B2 (ja) * 1992-04-28 2003-12-02 味の素株式会社 変異型アスパルトキナーゼ遺伝子
JPH07155184A (ja) * 1993-12-08 1995-06-20 Ajinomoto Co Inc 発酵法によるｌ−リジンの製造法
KR100268324B1 (ko) * 1995-06-07 2000-10-16 에가시라 구니오 L-리신의 제조 방법
CA2180202A1 (en) * 1995-06-30 1996-12-31 Mika Moriya Method of amplifying gene using artificial transposon
SK285201B6 (sk) 1996-12-05 2006-08-03 Ajinomoto Co., Inc. Rekombinantná DNA, autonómne reprodukovaná v bunkách koryneformnej baktérie, koryneformná baktéria a spôsob výroby L-lyzínu, vektor pVK7
JP4075087B2 (ja) 1996-12-05 2008-04-16 味の素株式会社 Ｌ−リジンの製造法
DE10031999A1 (de) 1999-09-09 2001-04-19 Degussa Verfahren zur fermentativen Herstellung von D-Pantothensäure unter Verwendung coryneformer Bakterien
DE19943587A1 (de) 1999-09-11 2001-03-15 Degussa Neue für das dapF-Gen codierende Nukleotidsequenzen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0857784A2 (en) 1996-12-05 1998-08-12 Ajinomoto Co., Inc. Method for producing L-lysine

Also Published As

Publication number Publication date
BRPI9706058B1 (pt) 2015-11-03
HU224409B1 (hu) 2005-08-29
PL190206B1 (pl) 2005-11-30
CN1161470C (zh) 2004-08-11
HUP9702361A2 (hu) 1999-06-28
JP4075087B2 (ja) 2008-04-16
CN1187539A (zh) 1998-07-15
HUP9702361A3 (en) 2002-12-28
US6221636B1 (en) 2001-04-24
JPH10165180A (ja) 1998-06-23
DE69736699T2 (de) 2007-09-20
EP0857784A2 (en) 1998-08-12
SK285146B6 (sk) 2006-07-07
ES2273356T3 (es) 2007-05-01
PL323545A1 (en) 1998-06-08
HU9702361D0 (en) 1998-03-02
DE69736699D1 (de) 2006-11-02
SK163597A3 (en) 1998-07-08
EP0857784A3 (en) 2002-10-16
DK0857784T3 (da) 2007-01-15
BR9706058A (pt) 1999-10-05

Similar Documents

Publication Publication Date Title
EP0857784B1 (en) Method for producing L-lysine
EP0811682B1 (en) Method of producing L-lysine
EP0854189B1 (en) Method for producing L-lysine
EP0841395B1 (en) Method of producing l-lysine
JP4168463B2 (ja) Ｌ−リジンの製造法
JPH0970291A (ja) 人工トランスポゾンを用いた遺伝子増幅方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: NAKAMATSU, TSUYOSHI, C/O AJINOMOTO CO., INC.

Inventor name: YOSHIHARA, YASUHIKO, C/O AJINOMOTO CO., INC.

Inventor name: SUGIMOTO, MASAKAZU, C/O AJINOMOTO CO., INC.

Inventor name: HAYAKAWA, ATSUSHI, C/O AJINOMOTO CO., INC.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20030214

AKX Designation fees paid

Designated state(s): DE DK ES FR GB IT NL

17Q First examination report despatched

Effective date: 20050304

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE DK ES FR GB IT NL

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69736699

Country of ref document: DE

Date of ref document: 20061102

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2273356

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: DEGUSSA GMBH

Effective date: 20070612

NLR1 Nl: opposition has been filed with the epo

Opponent name: DEGUSSA GMBH

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: EVONIK DEGUSSA GMBH

Effective date: 20070612

NLR1 Nl: opposition has been filed with the epo

Opponent name: EVONIK DEGUSSA GMBH

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

R26 Opposition filed (corrected)

Opponent name: EVONIK DEGUSSA GMBH

Effective date: 20070612

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20120802

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 69736699

Country of ref document: DE

Effective date: 20120802

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20161129

Year of fee payment: 20

Ref country code: GB

Payment date: 20161130

Year of fee payment: 20

Ref country code: DK

Payment date: 20161212

Year of fee payment: 20

Ref country code: FR

Payment date: 20161111

Year of fee payment: 20

Ref country code: NL

Payment date: 20161110

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20161111

Year of fee payment: 20

Ref country code: IT

Payment date: 20161221

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69736699

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20171204

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20171205

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20171204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20171204

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20171206